Lymphoma

Lymphoma is a cancer of the lymph nodes; classified as Hodgkin or non-Hodgkin lymphoma. Malignancy varies, and the prognosis can be from a few months to many years. Symptoms include enlarged lymph...

Hodgkin lymphoma

Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be l...

Lymphoma of bone

Primary CNS lymphoma

NonHodgkin lymphoma

Panobinostat: Phase II data

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

S. Korea's Celltrion Cancels Phase III Trials Of Lymphoma Generic

Celltrion, the South Korea-based drug maker the subject of widespread sell-out reports, has cancelled Phase III trials for a biosimilar of Roche's Rituxan (rituximab) for treating non-Hodgkins lymphom...

Chemo-Only Tx Works for Some Childhood Lymphoma (CME/CE, with audio)

(MedPage Today) -- Radiation can be safely eliminated from the regimen for children with low-risk Hodgkin lymphoma who respond well to chemotherapy, a phase II trial showed.

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin i...

Pfizer Stops Lymphoma Drug Late-Stage Trial Due To Ineffectiveness

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Monday said it has discontinued its Phase 3 study of inotuzumab ozogamicin in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who a...

Pfizer Aborts Japan And Global Phase 3 Non-Hodgkin’s Lymphoma Trials Of Inotuzumab Ozogamicin

Pfizer has aborted its joint international Phase III trials of inotuzumab ozogamicin for the treatment of non-Hodgkin’s lymphoma, the company announced May 22.

Late-stage trial fail for Lilly’s lymphoma drug

Lilly is to stop development of its lymphoma drug after it failed to meet its primary endpoint in phase 3 clinical trials.

Phase Ia/II, 2-arm, open-label, dose-escalation study of oral panobinostat administered via 2 dosing schedules in patients with advanced hematologic malignancies.

Panobinostat is a potent oral pan-deacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation, and induces apoptosis in leukemic cell lines. A phase Ia/I...

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.

Objective The objective was to determine the maximum tolerated dose and the dose-limiting toxicity of panobinostat (LBH589) when administered as a single agent to adult patients with advanced solid tu...

Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells.

Panobinostat, a pan-deacetylase inhibitor, represents a novel therapeutic option for cancer diseases. Besides its ability to block histone deacetylases (HDACs) by promoting histone hyperacetylation, p...

Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.

Histone deacetylase inhibitors (HDACIs) are promising antineoplastic agents for the treatment of cancer. Here we report that the lipid peroxidation end product 4-hydroxynonenal (HNE) significantly pot...

Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.

Inhibitors of protein deacetylases represent a novel therapeutic option for cancer diseases due to their effects on transcriptional regulation by interfering with histones acetylation and on several o...